Alector, Inc. is a clinical-stage biopharmaceutical company dedicated to pioneering new treatments for neurodegenerative disorders. A key program in its pipeline is AL001, a humanized recombinant monoclonal antibody currently undergoing Phase III clinical trials. This investigational therapy targets a range of severe conditions, including frontotemporal dementia, Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS). Additionally, AL101 is progressing through Phase I clinical trials for general neurodegenerative diseases, with a specific focus on Alzheimer's and Parkinson's. Further bolstering its Alzheimer's portfolio, Alector is evaluating AL002 in Phase II studies and AL003 in Phase I studies, both aimed at addressing Alzheimer's disease. In earlier-stage development, the company is also developing AL044, which targets the MS4A4A gene, identified as a risk factor for Alzheimer's disease. Alector has forged key partnerships to advance its mission. It collaborates with Adimab, LLC on antibody research and development. Furthermore, a significant strategic alliance with GlaxoSmithKline plc (GSK) focuses on the joint development and commercialization of monoclonal antibodies, specifically AL001 and AL101, for neurodegenerative conditions. Established in 2013, Alector's headquarters are located in South San Francisco, California.
zacks.comAlector (ALEC) Reports Q1 Loss, Lags Revenue Estimateszacks.comMay 7
globenewswire.comAlector Reports First Quarter 2026 Financial Results and Provides Business Updateglobenewswire.comMay 7
zacks.comWill Alector (ALEC) Report Negative Q1 Earnings? What You Should Knowzacks.comMay 7
globenewswire.comAlector to Discontinue Phase 2 PROGRESS-AD Trial of Nivisnebart (AL101/GSK4527226) in Early Alzheimer's Disease Following Interim Futility Analysisglobenewswire.comApr 29